This study is designed to assess the safety and feasibility of injecting mesenchymal stem cells (MSCs) derived from a patient’s own fat tissue into the cerebrospinal fluid after a severe traumatic spinal cord injury. It uses autologous, culture-expanded adipose-derived MSCs (AD-MSCs) delivered intrathecally and remains experimental, with the goal of exploring its potential to support recovery in individuals with spinal cord injury.

This study aims to determine whether allogeneic umbilical cord–derived mesenchymal stem cells (UC-MSCs) can be safely delivered into the cerebrospinal fluid of people with traumatic spinal cord injuries. Because this approach is still experimental, the findings may help guide the development of more effective therapies for spinal cord injuries in the future.